Menlo Ventures' 2026 State Of AI In Healthcare Report: Healthcare AI Spending Hits $3.7B, Up 2.5X As Growth Shifts From Paperwork To Drug Discovery And Patient Care


Date:

(MENAFN- GlobeNewsWire - Nasdaq) Life sciences AI spend surged 23x this year, clinical copilots grew 5.5x, and incumbents took 68% of new scribe dollars as healthcare AI moved beyond administrative work and closer to the patient

MENLO PARK, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Menlo Ventures, a leading venture capital firm investing at the forefront of artificial intelligence, today released its 2026: The State of AI in Healthcare report, finding that healthcare AI spending reached $3.7 billion, up 2.5x in a year. While AI's early successes in healthcare focused on administrative tasks like documentation and billing, the report finds the fastest growth now comes from drug discovery, clinical decision-making, and patient care.

“AI is transforming healthcare," said Greg Yap, Venture Partner at Menlo Ventures.“Earlier software could never automate healthcare's hardest work, but frontier models and AI agents are now expanding from the back office into the bench and the bedside. We're still in the early stages, but our research shows that the healthcare sector is leading the way in AI investment, driven by AI's potential to improve health outcomes and lower costs for everyone.”

Nowhere is that potential more evident than in life sciences, where AI spending surged 23x this year as pharmaceutical companies look to accelerate drug discovery and development.

“We expect AI to usher in a new era of drug discovery, bringing better medicines to patients faster,” said Johnny Hu, Ph.D., Principal at Menlo Ventures.“Today, developing a new drug takes more than a decade and billions of dollars with a 90% failure rate in the clinic. AI offers a chance to change those odds and develop medicines for previously intractable diseases. Ultimately, success won't be measured by how much pharma invests in AI, but by the new medicines that reach patients and the lives they improve.”

“In just one year, the healthcare AI market has changed dramatically,” said JP Sanday, Partner at Menlo Ventures.“Startups pioneered AI scribing, but incumbents moved quickly, with Microsoft and Epic now capturing roughly two of every three new scribe dollars. Meanwhile, growth is shifting to entirely new opportunities: life sciences AI spending surged 23x, clinical copilots grew 5.5x, and patient engagement grew 4.5x. For AI-native startups, the opportunity is no longer just making existing workflows more efficient. It's building products that fundamentally change how healthcare is delivered, making care more proactive, personalized, and accessible, rather than something patients have to navigate one appointment at a time.”

Key Findings

  • Healthcare is AI's largest vertical market. Spending grew 2.5x to $3.7 billion, more than legal and finance combined and more than double the next-largest vertical, legal ( $1.8 billion ). 50% of it goes to healthcare-specific applications, about twice the enterprise average, and providers account for 77% ( $2.9 billion ).
  • AI for drug discovery is breaking out. Life sciences AI spending surged 23x, from $30 million to $700 million, the fastest growth of any healthcare AI segment. 51% of pharma companies now run AI at scale, up from 15% a year ago, and 84% of R&D leaders expect AI to reduce development timelines by at least a year over the next three to five years. Proof is still ahead: 93% expect first approval of an AI-discovered drug within five years, but only 28% within two.
  • The provider market is evolving rapidly as incumbents strike back. Every major EHR now offers its own scribe, and this year incumbents captured 68% of new scribe dollars, growing their share to 46% of the $950 million market, up from 33% a year ago. AI-native scribes grew 28% but lost share, but are expanding into new areas like prior authorization.
  • AI innovation is moving closer to the patient. Clinical copilots grew 5.5x to $550 million and patient engagement AI grew 4.5x to $450 million, versus 1.6x for scribes and 1.3x for coding and billing.
  • Payers are paying for providers' AI, not their own. Payers' external AI spend was just $150 million ( 4% of the market), yet 43% of payers ( 57% of large payers) say provider AI coding has raised their medical cost trend in 2026, up from 23% in 2025. Prior authorization is now their top AI priority at 82%, up from 59%.

About the 2026 State of AI in Healthcare Report

Now in its second year, Menlo Ventures' The State of AI in Healthcare examines how healthcare organizations are buying and deploying AI, where they are spending, and which companies are capturing that spending.

The 2026 report draws on a survey o f 550 U.S. healthcare and life sciences executives at the director level and above who have participated in procuring an AI solution for their organization. Respondents include 150 technology decision-makers at provider organizations, 100 senior executives at health plans and benefits administrators, and 300 executives at pharmaceutical and biotech companies developing their own therapeutics.

The report explores how AI is transforming drug development, care delivery, and health insurance. It is authored by Menlo Ventures' healthcare investors Greg Yap, JP Sanday, Croom Beatty, Johnny Hu, Ph.D., Derek Xiao, and Sabrina Lu.

Read the full report, including detailed findings and methodology.

About Menlo Ventures
For 50 years, Menlo Ventures has backed companies that change how the world works, from Gilead Sciences to Uber to Anthropic. Today, Menlo is at the forefront of the AI transformation, investing across the technology stack, from foundation models (Anthropic ) and infrastructure (OpenRouter, Fireworks, Modal ) to breakthrough applications (Lovable, Higgsfield, Legora, OpenEvidence, and Wispr Flow ). Menlo's investment team brings together experienced investors, former founders, engineers, and technology executives who understand firsthand what it takes to build and scale a company. That experience informs every founder partnership, bringing practical insight and perspective to the challenges of building a business and scaling it into a market leader. Menlo invests from inception through growth across consumer, enterprise, and healthcare. In June 2026, the firm marked its 50th anniversary and announced $3 billion in fresh capital to back the next generation of AI companies.

Media Contact

Nectar Communications

...

Photos accompanying this announcement are available at:


MENAFN16112026004107003653ID1111968210


GlobeNewsWire - Nasdaq

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search